Akums Reports 13.9% Revenue Growth and Increased Profit in Q1 FY27
Akums Drugs and Pharmaceuticals Ltd., India's largest CDMO, reported strong financial results for Q1 FY27 ending June 30, 2026. Revenue rose 13.9% year-on-year to ₹1,167 crore, with EBITDA increasing 35.4% to ₹175 crore and PAT reaching ₹101 crore, up from ₹65 crore last year. The CDMO segment drove growth, with revenue at ₹964 crore and EBITDA up 36.8%. Company leaders highlighted healthy demand, operational improvements, and plans for sustainable growth.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 34/100.
Outlets measured: thetribune, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 10 Aug, 02:00 pm. Other outlets followed.